These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36915891)

  • 1. Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.
    Zhu J; Livasy C; Donahue EE; Symanowski JT; Grigg CM; Brown LC; Matulay JT; Kearns JT; Raghavan D; Burgess EF; Clark PE
    Transl Androl Urol; 2023 Feb; 12(2):228-240. PubMed ID: 36915891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma.
    Liu Y; Xu L; Zhu Y; Zhang W; Liu W; Liu H; Xu J
    Urol Oncol; 2015 Mar; 33(3):112.e1-8. PubMed ID: 25499921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
    Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
    Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.
    Fu H; Liu Y; Xu L; Liu W; Fu Q; Liu H; Zhang W; Xu J
    Tumour Biol; 2015 Aug; 36(8):5791-9. PubMed ID: 25716202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma.
    Liu Y; Liu Z; Fu Q; Wang Z; Fu H; Liu W; Wang Y; Xu J
    Urol Oncol; 2017 Jun; 35(6):349-355. PubMed ID: 28347658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.
    Fairey AS; Daneshmand S; Wang L; Schuckman A; Lieskovsky G; Djaladat H; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2014 Feb; 32(2):110-6. PubMed ID: 23499168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis.
    Zhou X; Sun L; Jing D; Xu G; Zhang J; Lin L; Zhao J; Yao Z; Lin H
    Front Physiol; 2018; 9():452. PubMed ID: 29765332
    [No Abstract]   [Full Text] [Related]  

  • 9. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients.
    Carlini MJ; Roitman P; Nuñez M; Pallotta MG; Boggio G; Smith D; Salatino M; Joffé ED; Rabinovich GA; Puricelli LI
    Lung Cancer; 2014 Apr; 84(1):73-8. PubMed ID: 24560493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?
    Tachibana I; Mahmoud M; Abedali ZA; Flack C; Adra N; Cheng L; Kaimaklitois HZ
    Urol Oncol; 2022 May; 40(5):196.e11-196.e16. PubMed ID: 35148949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
    Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
    Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.
    Kramer MW; Waalkes S; Serth J; Hennenlotter J; Tezval H; Stenzl A; Kuczyk MA; Merseburger AS
    Urol Int; 2011; 87(2):143-50. PubMed ID: 21757871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
    Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-8 and -9 as prognostic factors for cervical cancer.
    Beyer S; Wehrmann M; Meister S; Kolben TM; Trillsch F; Burges A; Czogalla B; Schmoeckel E; Mahner S; Jeschke U; Kolben T
    Arch Gynecol Obstet; 2022 Oct; 306(4):1211-1220. PubMed ID: 35377045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    Dis Markers; 2019; 2019():6702964. PubMed ID: 31534562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
    Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
    Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Yang F; Zhou Q; Meng L; Xing N
    Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
    Evers PD; Logan JE; Sills V; Chin AI
    World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.